In mouse models of SCLC, combined treatment with anti-VEGF and anti-PD-L1 agents significantly improved both PFS and OS compared with anti-PD-L1 alone, anti-VEGF alone or with standard combined cisplatin/etoposide chemotherapy. The gene discussed is VEGFA; the disease is small cell lung carcinoma.